Ferroptosis Mechanisms and Therapeutic Strategies in Cancer

Ferroptosis is a regulated form of cell death driven by iron-dependent lipid peroxidation and the failure of cellular antioxidant defences. Distinct from apoptosis or necrosis, ferroptosis involves the accumulation of reactive oxygen species within polyunsaturated phospholipids, leading to catastrophic membrane damage and cell demise. Central to this process is the balance between pro-oxidant pathways—such as iron import and lipid oxidation enzymes—and protective systems including glutathione peroxidase 4 (GPX4) and ferroptosis suppressor protein 1 (FSP1). In many cancers, alterations in iron metabolism, redox homeostasis and lipid remodelling create vulnerabilities that can be exploited by ferroptosis inducers. Strategies to trigger ferroptosis in tumours include direct inhibition of GPX4, disruption of cystine uptake, modulation of lipid biosynthesis and targeted delivery of redox-active compounds. Conversely, tumours may evade ferroptosis through upregulation of antioxidant pathways or metabolic rewiring, suggesting that combination approaches—pairing ferroptosis inducers with immune checkpoint inhibitors or conventional chemotherapies—offer promising avenues to overcome resistance. Emerging nanotechnologies and small-molecule libraries are expanding the toolkit for precise control over ferroptotic cell death, presenting new opportunities for selective cancer eradication while minimising off-target toxicity.

Research from Nature Portfolio

Recent studies have unveiled phase separation of FSP1 as a novel regulatory node in ferroptosis. Investigation of small-molecule inhibitors revealed that certain 3-phenylquinazolinones induce subcellular relocalisation of FSP1 into droplet-like condensates, impairing its membrane association and synergising with GPX4 inhibitors to potentiate lipid peroxidation. This mode of action underscores phase separation as an emergent mechanism to control ferroptotic sensitivity in therapy-resistant tumour models. Additionally, foundational work has characterised a distinct GPX4-dependent metabolic state in clear-cell carcinomas, identifying hypoxia-driven enrichment of polyunsaturated lipids as the molecular basis for heightened ferroptosis susceptibility. These insights highlight how tumour-specific metabolic programmes and protein condensation phenomena can be harnessed to develop precise ferroptosis-based anti-cancer interventions.

Ferroptosis Mechanisms and Therapeutic Strategies in Cancer publication trend

The graph below shows the total number of articles in ferroptosis mechanisms and therapeutic strategies in cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Ferroptosis: Iron-dependent regulated cell death marked by lethal lipid peroxidation.

Lipid peroxidation: Oxidative degradation of polyunsaturated fatty acids in membranes.

GPX4: Glutathione peroxidase 4, the primary enzyme reducing lipid hydroperoxides.

FSP1: Ferroptosis suppressor protein 1, an alternative oxidoreductase that prevents lipid damage.

Phase separation: Biophysical process where proteins form membrane-less condensates influencing biochemical activity.

References

1. Phase separation of FSP1 promotes ferroptosis. Nature (2023).
2. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nature Communications (2019).
3. Understanding the Novel Approach of Nanoferroptosis for Cancer Therapy. Nano-Micro Letters (2024).
4. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biology (2019).